Panbela Therapeutics, Inc. (NASDAQ:PBLA – Get Free Report)’s share price rose 2.4% during mid-day trading on Tuesday . The company traded as high as $0.34 and last traded at $0.34. Approximately 5,495 shares traded hands during trading, a decline of 98% from the average daily volume of 238,504 shares. The stock had previously closed at $0.34.
Wall Street Analyst Weigh In
Separately, HC Wainwright reissued a “neutral” rating on shares of Panbela Therapeutics in a research note on Thursday, August 15th.
View Our Latest Research Report on Panbela Therapeutics
Panbela Therapeutics Stock Performance
Panbela Therapeutics (NASDAQ:PBLA – Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($1.47) earnings per share for the quarter, beating the consensus estimate of ($2.07) by $0.60.
About Panbela Therapeutics
Panbela Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company’s lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial.
Further Reading
- Five stocks we like better than Panbela Therapeutics
- Why is the Ex-Dividend Date Significant to Investors?
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- What is Short Interest? How to Use It
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- Are Penny Stocks a Good Fit for Your Portfolio?
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Panbela Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Panbela Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.